Key result
The 2013 ACC/AHA guidelines recommended statins to more HIV-infected adults than ATP III guidelines (26% vs 14%, P<0.001), though both missed the majority with carotid plaque.
Why the study?
Do the 2013 ACC/AHA cholesterol guidelines recommend statin therapy to a greater proportion of HIV-infected adults with carotid atherosclerosis compared to the 2004 ATP III guidelines?
Cohort (n=352)
Do the 2013 ACC/AHA cholesterol guidelines recommend statin therapy to a greater proportion of HIV-infected adults with carotid atherosclerosis compared to the 2004 ATP III guidelines?
While the 2013 ACC/AHA guidelines recommend statins to more HIV-infected adults than the ATP III guidelines, both miss the majority of patients with subclinical carotid atherosclerosis, which is an independent predictor of mortality.
Answers are grounded in this paper and cite their sources.
Current guidelines miss most HIV adults with plaque; hypothesis-generating for HIV-specific statin risk tools.
Background— Although HIV is associated with increased atherosclerotic cardiovascular disease (CVD) risk, it is unknown whether guidelines can identify HIV-infected adults who may benefit from statins. We compared the 2013 American College of Cardiology/American Heart Association and 2004 Adult Treatment Panel III recommendations in HIV-infected adults and evaluated associations with carotid artery intima-media thickness and plaque. Methods and Results— Carotid artery intima-media thickness was measured at baseline and 3 years later in 352 HIV-infected adults without clinical atherosclerotic CVD and not on statins. Plaque was defined as IMT >1.5 mm in any segment. At baseline, the median age was 43 (interquartile range, 39–49), 85% were men, 74% were on antiretroviral medication, and 50% had plaque. The American College of Cardiology/American Heart Association guidelines were more likely to recommend statins compared with the Adult Treatment Panel III guidelines, both overall (26% versus 14%; P <0.001), in those with plaque (32% versus 17%; P =0.0002), and in those without plaque (16% versus 7%; P =0.025). In multivariable analysis, older age, higher low-density lipoprotein cholesterol, pack per year of smoking, and history of opportunistic infection were associated with baseline plaque. Baseline IMT (hazard ratio, 1.18 per 10% increment; 95% confidence interval, 1.05–1.33; P =0.005) and plaque (hazard ratio, 2.06; 95% confidence interval, 1.02–4.08; P =0.037) were each associated with all-cause mortality, independent of traditional CVD risk factors. Conclusions— Although the American College of Cardiology/American Heart Association guidelines recommended statins to a greater number of HIV-infected adults compared with the Adult Treatment Panel III guidelines, both failed to recommend therapy in the majority of HIV-affected adults with carotid plaque. Baseline carotid atherosclerosis but not atherosclerotic CVD risk scores was an independent predictor of mortality. HIV-specific guidelines that include detection of subclinical atherosclerosis may help to identify HIV-infected adults who are at increased atherosclerotic CVD risk and may be considered for statins.
No takes yet. Share an insight, caveat, or question.
Phan et al. (2017) conducted a cohort in HIV infection without clinical atherosclerotic CVD (n=352). 2013 ACC/AHA guidelines vs. 2004 ATP III guidelines was evaluated on Recommendation for statin therapy (p=<0.001). The 2013 ACC/AHA guidelines recommended statins to more HIV-infected adults than ATP III guidelines (26% vs 14%, P<0.001), though both missed the majority with carotid plaque.
Synapse has enriched 10 related papers. Consider them for comparative context: